story of the week
Atezolizumab With or Without Cobimetinib vs Regorafenib in Previously Treated Metastatic Colorectal Cancer
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Atezolizumab With or Without Cobimetinib Versus Regorafenib in Previously Treated Metastatic Colorectal Cancer (IMblaze370): A Multicentre, Open-Label, Phase 3, Randomised, Controlled Trial
Lancet Oncol 2019 Apr 16;[EPub Ahead of Print], C Eng, TW Kim, J Bendell, G Argilés, NC Tebbutt, M Di Bartolomeo, A Falcone, M Fakih, M Kozloff, NH Segal, A Sobrero, Y Yan, I Chang, A Uyei, L Roberts, F CiardielloFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.